[go: up one dir, main page]

JO3559B1 - جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه - Google Patents

جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه

Info

Publication number
JO3559B1
JO3559B1 JOP/2016/0034A JOP20160034A JO3559B1 JO 3559 B1 JO3559 B1 JO 3559B1 JO P20160034 A JOP20160034 A JO P20160034A JO 3559 B1 JO3559 B1 JO 3559B1
Authority
JO
Jordan
Prior art keywords
migraine headache
antibody
treating
methods
cgrp receptor
Prior art date
Application number
JOP/2016/0034A
Other languages
English (en)
Inventor
Sun Hong
vargas Gabriel
Dunayevich Eduardo
Lenz Robert
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53969433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3559(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of JO3559B1 publication Critical patent/JO3559B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بطرق للوقاية من الصداع النصفي باستخدام أجسام مضاد مستقبلة ضد-</span>CGRP<span dir="RTL"> أو شدفات ربط. على وجه التحديد، يتم الكشف عن طرق لمنع أو تقليل حدوث الصداع النصفي لدى مريض يحتاج لها وتشتمل على إعطاء المريض مستقبلة ضد-</span>CGPR<span dir="RTL"> أو شدفة ربط وفقاً لأنظمة جرعات محددة. كما يتم الكشف عن تركيبات صيدلانية وأجهزة إعطاء تشتمل على أجسام مضادة مستقبلة ضد-</span>CGPR<span dir="RTL"> أو شدفات ربط للاستخدام في الطرق.</span>
JOP/2016/0034A 2015-04-24 2016-03-03 جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه JO3559B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562152708P 2015-04-24 2015-04-24

Publications (1)

Publication Number Publication Date
JO3559B1 true JO3559B1 (ar) 2020-07-05

Family

ID=53969433

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2020/0116A JOP20200116A1 (ar) 2015-04-24 2015-04-24 طرق لعلاج أو الوقاية من الصداع النصفي
JOP/2016/0034A JO3559B1 (ar) 2015-04-24 2016-03-03 جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2020/0116A JOP20200116A1 (ar) 2015-04-24 2015-04-24 طرق لعلاج أو الوقاية من الصداع النصفي

Country Status (31)

Country Link
US (3) US10259877B2 (ar)
EP (2) EP3285803B1 (ar)
JP (5) JP6392471B2 (ar)
KR (1) KR102464415B1 (ar)
CN (2) CN113908268B (ar)
AU (2) AU2015392215B2 (ar)
BR (1) BR112017022772A2 (ar)
CA (1) CA2984254C (ar)
CL (1) CL2017002686A1 (ar)
CY (1) CY1123211T1 (ar)
DK (2) DK3285803T3 (ar)
ES (2) ES3005228T3 (ar)
FI (1) FI3653225T3 (ar)
HR (2) HRP20200056T1 (ar)
HU (2) HUE048528T2 (ar)
IL (2) IL291153B2 (ar)
JO (2) JOP20200116A1 (ar)
LT (2) LT3653225T (ar)
MA (2) MA41932B1 (ar)
MX (2) MX387530B (ar)
PH (1) PH12017501934A1 (ar)
PL (2) PL3653225T3 (ar)
PT (2) PT3285803T (ar)
RS (2) RS59912B1 (ar)
RU (1) RU2707745C2 (ar)
SG (2) SG11201708607WA (ar)
SI (2) SI3653225T1 (ar)
SM (1) SMT202000067T1 (ar)
TW (2) TWI799849B (ar)
WO (1) WO2016171742A1 (ar)
ZA (1) ZA201707179B (ar)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
BR112016021423A2 (pt) 2014-03-21 2017-11-14 Teva Pharmaceuticals Int Gmbh anticorpos antagonistas direcionados contra peptídeo relacionado ao gene de calcitonina e métodos que utilizam o mesmo
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
CA3055195A1 (en) 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center, Inc. Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
US20200207844A1 (en) * 2017-09-12 2020-07-02 Igc Bio, Inc. Anti-vegf antibody
SG11202006610YA (en) 2018-01-12 2020-08-28 Amgen Inc Pac1 antibodies and uses thereof
JP2021519790A (ja) * 2018-04-02 2021-08-12 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
TW202019459A (zh) * 2018-07-05 2020-06-01 愛爾蘭商歐樂根製藥國際有限公司 Cgrp拮抗劑及梭菌衍生物之組合療法
CN113227140A (zh) 2019-01-08 2021-08-06 H.隆德贝克有限公司 使用抗cgrp抗体急性治疗和快速治疗头痛
GEAP202515803A (en) * 2019-05-02 2025-06-10 H Lundbeck As Treatment of headache using anti-cgrp antibodies
US20210121541A1 (en) 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
WO2021005497A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
WO2021005493A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and botulinum toxins for the treatment of inflammatory and neurologic disorders
JP7744344B2 (ja) * 2019-12-18 2025-09-25 キュラセン セラピューティクス インコーポレイテッド 神経系疾患および障害を改善するための方法
BR102020007149A8 (pt) 2020-04-06 2023-09-26 H Lundbeck As Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
AU2021284378A1 (en) 2020-06-03 2023-01-19 Miotox, Llc Zonal and targeted methods and uses for treating a migraine disorder
EP4301362A1 (en) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
KR102775899B1 (ko) 2023-12-19 2025-02-28 한림대학교 산학협력단 삽화성 편두통 및 만성 편두통 진단을 위한 정보제공 방법, 장치 및 컴퓨터 프로그램

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
DK0640131T3 (da) 1992-03-17 1999-11-01 Novartis Ag Gensplejsere antistoffer
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
DE69433747D1 (de) 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1998003534A1 (en) 1996-07-23 1998-01-29 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
CA2461917C (en) 2001-09-27 2012-01-17 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
AU2003260944B2 (en) 2002-08-12 2009-05-14 Actavis Group Hf. Use of CGRP antagonist compounds for treatment of psoriasis
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
RU2378285C2 (ru) 2004-02-11 2010-01-10 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
ATE521638T1 (de) 2004-12-21 2011-09-15 Medimmune Ltd Gegen angiopoietin-2 gerichtete antikörper und anwendungen davon
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
EP1900374B1 (en) 2005-06-16 2014-03-12 Takayuki Shindo Angiogenetic agent containing adrenomedulin as the active ingredient
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
WO2007054809A2 (en) 2005-11-14 2007-05-18 Rinat Neuroscience Corp. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007061692A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam tricyclic cgrp receptor antagonists
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
CA2650932C (en) 2006-05-09 2013-01-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
RU2009107277A (ru) 2006-08-03 2010-09-10 Астразенека Аб (Se) АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ
EP2146715A4 (en) 2007-04-11 2011-08-31 Merck Sharp & Dohme CGR-RECEPTOR ANTAGONISTS WITH TERTIARY AMID, SULFONAMIDE, CARBAMATE AND UREA END GROUPS
US8143266B2 (en) 2007-04-16 2012-03-27 Merck, Sharp & Dohme Corp Aryl heterocyclic CGRP receptor antagonists
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
ES2584907T3 (es) 2008-03-04 2016-09-30 Labrys Biologics Inc. Métodos para tratamiento del dolor inflamatorio
CA2727243A1 (en) 2008-06-12 2009-12-17 Merck Sharp & Dohme Corp. Branched 3- and 6-substituted quinolines as cgrp receptor antagonists
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
EP2339919B1 (en) 2008-09-18 2014-03-12 Merck Sharp & Dohme Corp. Bicyclic dihydroimidazolone cgrp receptor antagonists
AU2009298752A1 (en) 2008-10-03 2010-04-08 Merck Sharp & Dohme Corp. CGRP receptor antagonists
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
MX2012002464A (es) 2009-08-28 2012-03-14 Rinat Neuroscience Corp El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral.
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
EA033109B1 (ru) * 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
EP3662932B1 (en) 2011-05-20 2021-04-07 H. Lundbeck A/S Anti-cgrp compositions and use thereof
RS66303B1 (sr) * 2011-05-20 2025-01-31 H Lundbeck As Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
ES2770976T3 (es) 2013-03-15 2020-07-06 Amgen Inc Anticuerpos PAC1 humanos
BR112016021423A2 (pt) 2014-03-21 2017-11-14 Teva Pharmaceuticals Int Gmbh anticorpos antagonistas direcionados contra peptídeo relacionado ao gene de calcitonina e métodos que utilizam o mesmo
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6956631B2 (ja) * 2014-09-15 2021-11-02 アムジェン インコーポレイテッド 二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用

Also Published As

Publication number Publication date
TWI728953B (zh) 2021-06-01
TWI799849B (zh) 2023-04-21
CN113908268A (zh) 2022-01-11
SG10202004282RA (en) 2020-06-29
SI3653225T1 (sl) 2025-02-28
MA41932B1 (fr) 2020-04-30
PL3653225T3 (pl) 2025-03-10
MX2021013327A (es) 2021-11-17
KR20180002711A (ko) 2018-01-08
CA2984254C (en) 2019-09-24
EP3653225A1 (en) 2020-05-20
WO2016171742A1 (en) 2016-10-27
PT3285803T (pt) 2020-02-18
US20160311913A1 (en) 2016-10-27
HRP20200056T1 (hr) 2020-04-03
JP2019001800A (ja) 2019-01-10
CY1123211T1 (el) 2021-12-31
RU2017140789A3 (ar) 2019-05-24
LT3285803T (lt) 2020-02-10
AU2015392215A1 (en) 2017-11-09
IL255114B (en) 2022-04-01
MA51815A (fr) 2020-12-23
ES3005228T3 (en) 2025-03-14
HK1250914A1 (en) 2019-01-18
EP3285803A1 (en) 2018-02-28
RU2017140789A (ru) 2019-05-24
US10259877B2 (en) 2019-04-16
SI3285803T1 (sl) 2020-02-28
JP2020143115A (ja) 2020-09-10
SMT202000067T1 (it) 2020-03-13
KR102464415B1 (ko) 2022-11-04
FI3653225T3 (fi) 2024-12-19
BR112017022772A2 (pt) 2018-07-31
PT3653225T (pt) 2024-12-30
HUE048528T2 (hu) 2020-07-28
JP6707590B2 (ja) 2020-06-10
US20190256607A1 (en) 2019-08-22
MX387530B (es) 2025-03-18
EP3285803B1 (en) 2019-12-18
PL3285803T3 (pl) 2020-06-01
RU2707745C2 (ru) 2019-11-29
US20230020514A1 (en) 2023-01-19
HRP20241717T1 (hr) 2025-02-14
CN108156814B (zh) 2021-07-09
RS59912B1 (sr) 2020-03-31
CN113908268B (zh) 2025-06-10
JP2022126724A (ja) 2022-08-30
JP2018513871A (ja) 2018-05-31
AU2022204866A1 (en) 2022-08-18
EP3653225B1 (en) 2024-10-02
IL291153B2 (en) 2023-06-01
JOP20200116A1 (ar) 2017-06-16
ZA201707179B (en) 2020-01-29
CN108156814A (zh) 2018-06-12
US11466090B2 (en) 2022-10-11
MX2017013627A (es) 2018-07-06
TW202130369A (zh) 2021-08-16
RS66352B1 (sr) 2025-01-31
JP6392471B2 (ja) 2018-09-19
SG11201708607WA (en) 2017-11-29
CA2984254A1 (en) 2016-10-27
ES2771925T3 (es) 2020-07-07
LT3653225T (lt) 2025-01-10
DK3653225T3 (da) 2025-01-02
TW201637667A (zh) 2016-11-01
PH12017501934A1 (en) 2018-03-19
DK3285803T3 (da) 2020-02-17
HUE069646T2 (hu) 2025-03-28
JP7544766B2 (ja) 2024-09-03
CL2017002686A1 (es) 2018-05-11
AU2015392215B2 (en) 2022-04-07
IL291153A (en) 2022-05-01
AU2022204866B9 (en) 2025-08-14
JP2024138374A (ja) 2024-10-08
IL255114A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
JO3559B1 (ar) جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX384192B (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
PH12018500642A1 (en) Anti-garp antibody
JOP20200312A1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
MY201148A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2018003713A (es) Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
PH12021551494A1 (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
MY184189A (en) Methods of treating nail and scalp psoriasis
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
HK1253098A1 (zh) 用於治疗癌症的mdm2抑制剂的给药方案
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
BR112022010934A2 (pt) Métodos para tratar copd administrando um antagonista de il-33
JOP20210247A1 (ar) علاج الصداع باستخدام أجسام مضادة لـ cgrp
EP3279218A4 (en) Immunizing peptide, method for producing immunizing peptide, pharmaceutical composition for immune disorders containing same, and method for treating immune disorders
ZA202002480B (en) Methods for treating or preventing asthma by administering an il-4r antagonist